Asset Details
Do you wish to reserve the book?
The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy
Do you wish to request the book?
The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy
2011
Overview
Skeletal muscle atrophy occurs in many chronic diseases and disuse conditions. Its severity reduces patient recovery, independence and quality of life. The discovery of two muscle-specific E3 ubiquitin ligases, MAFbx/atrogin-1 and Muscle RING Finger-1 (MuRF1), promoted an expectation of these molecules as targets for therapeutic development. While numerous studies have determined the conditions in which MAFbx/atrogin-1 and MuRF1 mRNA levels are regulated, few studies have investigated their functional role in skeletal muscle. Recently, studies identifying new target substrates for MAFbx/atrogin-1 and MuRF1, outside of their response to the initiation of muscle atrophy, suggest that there is more to these proteins than previously appreciated. This review will highlight our present knowledge of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy, the impact of potential therapeutics and their known regulators and substrates. Finally, we will comment on new approaches that may expand our knowledge of these two molecules in their control of skeletal muscle function.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
Acquired Immunodeficiency Syndrome - physiopathology
/ Animals
/ Biomedical and Life Sciences
/ Diabetes Mellitus - physiopathology
/ Humans
/ Immobilization - adverse effects
/ Muscle Proteins - physiology
/ Muscular Atrophy - metabolism
/ Pulmonary Disease, Chronic Obstructive - physiopathology
/ Renal Insufficiency - physiopathology
/ SKP Cullin F-Box Protein Ligases - physiology
